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The present study was designed to examine whether different p53 haplotypes of exon 4–intron 3–intron 6 affect the frequency of
mutations and loss of heterozygosity (LOH) of the p53 gene in male oral squamous cell carcinomas (OSCCs) in Taiwan. We found
that individuals without two Pro-W-G alleles had significantly higher frequency of p53 mutations than those with two Pro-W-G alleles
(odds ratio (OR)¼1.98; 95% confidence interval (CI), 1.10–3.56). Out of the 172 p53 gene exon 4 informative male OSCCs, 72
(41.9%) showed LOH. Among these 72 OSCCs with LOH, the frequency of Pro allele loss was 73.6% (53/72). It is notable that
alcohol drinking increased the frequency of Arg allele loss (OR¼10.56; 95% CI, 1.23–234.94) in OSCCs from patients who both
smoked cigarettes and chewed areca quid (AQ). The frequency of LOH of p53 was not different between p53-mutated OSCCs and
p53-normal OSCCs. Thus, the present study revealed that (a) the Arg allele is associated with p53 mutations, (b) the Pro allele is
preferentially lost in OSCCs associated with cigarette smoking and AQ chewing, while the frequency of Arg allele loss is increased
with alcohol drinking, and (c) haploinsufficiency of p53 is in itself likely to contribute to tumour progression in Taiwanese OSCCs.
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Oral cancer is the sixth most common cancer in the world (Nair
et al, 1996), and was accounted to be the fifth leading cause of male
cancer mortality in Taiwan in 2002 (Department of Health, ROC,
2003). Epidemiological studies have clearly indicated that areca
quid (AQ) chewing, cigarette smoking and alcohol are the major
risk factors for oral squamous cell carcinoma (OSCC) (IARC, 1985;
Ko et al, 1995). In Taiwan, approximately 80% of all oral cancer
patients are associated with the AQ chewing habit (Ko et al, 1995).
In addition, most Taiwanese AQ chewers are also smokers and
alcohol drinkers.
The p53 tumour suppressor protein is involved in cell-cycle
control, apoptosis and DNA repair (Vogelstein et al, 2000). The
importance of the p53 tumour suppressor gene in the process of
carcinogenesis is well established (Hussain and Harris, 1998).
Mutation at p53 has been demonstrated in over 50% of human
cancers, especially tobacco-related cancers. Recently, we reported
an important contributive role for tobacco carcinogens in p53
mutation for a series of Taiwanese patients with OSCCs (Hsieh
et al, 2001). The most prevalent types of p53 mutation found in
Taiwanese OSCCs were G:C to A:T transitions and G:C to T:A
transversions. Studies have demonstrated that these types of
mutations are the most common mutations observed in animals
treated with NNK or other tobacco nitrosamines (Belinsky et al,
1991; Oreffo et al, 1993; Ronai et al, 1993; Chang et al, 1996).
Evidence from the literature also indicates that NNK-associated
DNA adducts, in addition to being repaired by the nucleotide
excision repair pathway, are also repaired by base excision repair
(Cloutier and Castonguay, 1998). XRCC1 plays an important role
in the base excision repair pathway, and interacts with DNA
polymerase b, PARP and DNA ligase III. It also has a BRCT
domain, which is characteristic of proteins involved in cycle
checkpoint functions and this domain may be responsive to DNA
damage (Caldecott et al, 1996; Masson et al, 1998). Abdel-Rahman
and El-Zein (2000) found that the 399Gln polymorphism of XRCC1
appeared to be associated with reduced repair of NNK-induced
genetic damage in cultured human lymphocytes. We found that
OSCC patients with an XRCC1 399Gln/Gln genotype exhibited a
significantly higher frequency of p53 mutation than those with an
Arg/Gln or an Arg/Arg genotype (Hsieh et al, 2003).
It is known that one type of p53 polymorphism that is found in
the general population results in either an Arg or a Pro at residue
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s72 and this produces a marked change in the structure of the p53
protein (Matlashewski et al, 1987). Recently, Marin et al (2000) and
Tada et al (2001) have reported that the Arg72 allele was
preferentially mutated and retained in various human tumours.
In addition to codon 72 polymorphism, Wu et al (2002) found that
cells with different p53 haplotypes of exon 4–intron 3–intron 6
showed different capacities for DNA repair and apoptosis. In this
study, we test whether different p53 haplotypes of exon 4–intron
3–intron 6 would associate with p53 mutations and examine the
role of the Arg72 allele in loss of heterozygosity (LOH) of p53 gene
in Taiwanese OSCCs.
MATERIALS AND METHODS
Patients, tissue specimens and clinical diagnosis
This study was approved by the Institutional Review Board, Chang
Gung Memorial Hospital. A total of 715 OSCC patients treated at
Chang Gung Memorial Hospital, Lin-Kuo during the period from
March 1999 to December 2001 were recruited consecutively for
participation in the present study. All cases were histologically
confirmed. Female patients (n¼42) were excluded from this study
because of an insufficient number. Those who were diagnosed as
nonsquamous cell carcinoma (n¼44) were also excluded. Thus, a
total of 629 male OSCC patients, including 237 patients previously
studied (Hsieh et al, 2003), were included for the present analysis.
All patients gave informed consent for participation and were
interviewed uniformly before surgery by a well-trained interviewer.
The questionnaire used in the interview sought detailed informa-
tion on current and past cigarette smoking, alcohol drinking and
AQ chewing habits, occupational history, family disease history,
dietary history and general demographic data.
For each case, two samples were taken, a tumour sample and a
sample from the adjacent normal nontumour tissue. These samples
were surgically dissected into small pieces, frozen immediately in
liquid nitrogen and stored at  801C. In addition, 10ml of venous
blood was drawn into heparinised tubes (Vacutainer) and stored at
41C. The whole blood was separated into plasma, buffy coat cells
and red blood cells by centrifugation within 18h of obtaining the
blood, and stored in a  801C freezer. Genomic DNA for
genotyping was extracted and purified from the buffy coat cells
as previously described (Hsieh et al, 2003).
The surgically removed samples were sent to the Department of
Pathology, Chang Gung Medical Center for examination and
scored according to the recommendations for the reporting of
specimens containing oral cavity and oropharynx neoplasms by
the Associations of Directors of Anatomic and Surgical Pathology
(ADASP) (2000). Histology diagnosis was defined as squamous cell
carcinoma, verrucous carcinoma, cylindric cell carcinoma, ade-
noid cystic carcinoma, mucoepidermoid carcinoma and adeno-
carcinoma.
As reference male controls, 371 subjects with available blood
samples selected from 3000 random samples of the Taiwanese
general population collected to study blood lead concentrations
were included in this study (Hsieh et al, 2000).
Tobacco, AQ and alcohol use
Study participants were asked if they had ever smoked cigarettes,
chewed AQ or drank alcohol on a regular basis (at least once a
week for 1 year). Those who responded ‘yes’ to these questions
were classified as tobacco, AQ and alcohol users, respectively.
p53 genotype and haplotype determination
The genotype of p53 for intron 3, exon 4 and intron 6 was
determined by PCR-RFLP (Wu et al, 2002) followed by poly-
acrylamide gel electrophoresis. For the exon 4 codon 72
polymorphism, a 396bp DNA fragment was amplified and digested
with BstUI. The Arg/Arg homozygotes showed two bands of 165
and 231bp, the Arg/Pro heterozygotes showed three bands of 165,
231 and 396bp and the Pro/Pro homozygotes showed only one
band of 396bp. For the intron 3 polymorphism, either a 180 or
196bp DNA fragment was amplified. The WW (without the 16bp
duplication) homozygotes showed one band of 180bp, the WM
heterozygotes showed two bands of 180 and 196bp and the MM
(with the 16bp duplication) homozygotes showed only one band
of 196bp. For the intron 6 polymorphism, a 404bp DNA fragment
was amplified and digested with MspI. The GG homozygotes
showed two bands of 68 and 336bp, the GA heterozygotes showed
three bands of 68, 336 and 404bp and the AA homozygotes showed
only one band of 404bp.
p53 haplotypes could be inferred directly from the genotyping
results for the individuals who were heterozygous at only one site
or at no sites. For the other individuals, allele cloning and PCR-
RFLP methods were used to determine the haplotypes. A 1.6kb
fragment of p53 gene containing intron 3, exon 4 and intron 6 was
amplified, cloned with the pCR
s 2.1 vector (Invitrogen, Carlsbad,
CA, USA) and transformed into INVaF0 cells. At least five white
clones of each case were genotyped for intron 3, exon 4 and intron
6 by PCR-RFLP as described above.
Mutation and LOH analysis of the p53 gene
According to Soussi and Beroud (2001), 13.6% of p53 mutations
were located outside exons 5–8, with a significant number of
mutations in exons 4, 10 and, to a lesser extent, 9. Therefore,
single-stranded conformation polymorphism (SSCP) analysis was
used to analyse tumour samples for mutations within exons 4–10
of the p53 gene. The lengths of PCR fragments for our SSCP
analysis were in the range of 135–245bp and the sensitivity and
specificity of this technique to detect mutations even if only
present in a low amount is more than 90%. Cases displaying an
altered electrophoretic mobility were reamplified in another
reaction and analysed by direct sequencing of both strands to
confirm and characterise the nature of the mutation (Hsieh et al,
2001).
For individuals who were heterozygous at exon 4 codon 72, DNA
from their tumour tissues was used to amplify the 396bp exon 4
fragment, which was digested with BstUI, purified and analysed by
denaturing high-performance liquid chromatography (DHPLC)
(WAVE DNA Fragment Analysis System, Omaha, NE, USA)
(Kleymenova and Walker, 2001). PCR was performed for 27 cycles
so that the reaction was still in the exponential phase of
amplification. Then, DHPLC analysis was performed at 501C and
flow rate 0.9mlmin
 1 in a gradient of acetonitrile in 0.1 M
triethylammonium acetate: the gradient started at 8.75%, increased
in 3.5min to 13.75%, then increased in 7min to 16.25%, was
constant for 1min, then increased in 1min to 75%, was constant
for 1min (wash), then decreased in 1min to 8.75% and finally was
constant for 1min (equilibration). The ratio of the peak area
between the 396bp fragment, the Pro allele, and the 231bp
fragment, the Arg allele, was calculated. Tumour DNA with a ratio
outside the 95% confidence interval (CI) of the mean ratio from 30
normal controls was considered as positive for LOH in the p53
gene (representative results by DHPLC are shown in Figure 1).
Statistical analysis
Statistical analyses were performed with the Statistical Analysis
System (SAS) version 8.1. The association between the frequency
of p53 mutation or LOH and genotype/haplotype of p53 intron 3,
exon 4 and intron 6 was examined by w
2 or Fisher’s exact test.
Multiple logistic regression model was further used to assess the
major factors attributed to the frequency of p53 mutation.
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A total of 629 consecutive patients with a diagnosis of OSCC were
enrolled in the study. The demographic information of the patients
is shown in Table 1. The most common primary sites were the
bucca and the tongue. In all, 94% (591/628) of the patients had
smoked at some time, 62.4% (389/623) were users of alcohol at
some time and 90.8% (570/628) had chewed AQ at some time.
As shown in Table 2, the frequencies of Arg72, W allele of intron
3 and G allele of intron 6 were 0.58, 0.97 and 0.97, respectively, in
the referent male controls. The frequencies of the Arg/Arg, Arg/Pro
and Pro/Pro genotypes for codon 72 were 34.50, 47.71 and 17.79%,
respectively. The frequencies of the WW, WM and MM genotypes
for intron 3 were 94.07, 5.39 and 0.54%, respectively. The
frequencies of the GG, GA and AA genotypes for intron 6 were
94.07, 5.39 and 0.54%, respectively. All of the distributions were in
Hardy–Weinberg equilibrium. The most common two haplotypes
of exon 4–intron 3–intron 6 were Arg-W-G (58.36%), followed by
Pro-W-G (38.41%). All other types were relatively rare. It is
interesting to note that these rare haplotypes were slightly
associated with a risk of oral cancer (odds ratio (OR)¼1.72;
95% CI, 0.97–3.07).
Tumour samples from 272 OSCC patients without antecedent
treatment, including 237 cases published previously (Hsieh et al,
2001), were examined for mutations within exons 4–10 of the p53
gene by PCR-SSCP. Based on Table 2, the associations between the
common haplotypes of p53 gene and cancer risk were slightly
different in different sites of oral cancer (oral cavity cancer vs
hypopharyngeal/oropharyngeal cancer). The cases of hypophar-
yngeal and oropharyngeal cancer were excluded for statistical
analysis (n¼18). Of the 254 oral cavity OSCCs, 128 (50.4%)
showed a p53 gene mutation at exons 4–10. Individuals with either
one or no Pro-W-G alleles were more likely to have p53 gene
mutations (OR¼1.99; 95% CI, 1.08–3.68; Table 3) than those with
two Pro-W-G alleles. After adjustment for age, cigarette smoking,
alcohol drinking, AQ chewing and XRCC1 399Gln polymorphism,
individuals with one or no Pro-W-G alleles still had a higher
frequency of p53 mutations (OR¼1.98; 95% CI, 1.10–3.56) than
those with two Pro-W-G alleles.
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Figure 1 LOH analysis of p53 gene by DHPLC. The analysis was
performed at 501C and flow rate 0.9mlmin
 1 in a gradient of acetonitrile
in 0.1 M triethylammonium acetate: the gradient started at 8.75%, increased
in 3.5min to 13.75%, then increased in 7min to 16.25%, was constant for
1min, then increased in 1min to 75%, was constant for 1min (wash), then
decreased in 1min to 8.75% and finally was constant for 1min
(equilibration).
Table 1 Characteristics of the male patients with OSCCs (n¼629)
Age (years)
Mean7s.d. 49.93710.67
Range 25–78
Site of primary tumour (N (%))
Oral cavity 523 (83.2)
Lip 19 (3.0)
Tongue 175 (27.8)
Mouth floor 22 (3.5)
Buccal mucosa 208 (33.1)
Gingiva 53 (8.4)
Hard palate 13 (2.1)
Retromolar trigone 33 (5.2)
Oropharynx 49 (7.8)
Hypopharynx 57 (9.1)
Clinical stage (N (%))
Stage I 79 (12.8)
Stage II 136 (22.1)
Stage III 125 (20.3)
Stage IV 275 (44.7)
Cigarette smoker at some time (N (%)) 591 (94.1)
Alcohol drinker at some time (N (%)) 389 (62.4)
Areca quid chewer at some time (N (%)) 570 (90.8)
Table 2 Risk estimates for p53 haplotypes in male OSCC patients and control subjects
Controls
Oral cavity cancer patients Other OSCC cancer patients
a All OSCC
patients
Genotype (exon 4–
intron 3–intron 6)
Haplotype (exon
4–intron 3–intron
6) N (%) N (%) OR (95% CI) N (%) OR (95% CI) OR (95% CI)
Arg/Arg-WW
b-GG Arg-W-G/Arg-W-G 128 (34.5) 148 (28.3) 1 38 (35.9) 1 1
Arg/Pro-WW-GG Arg-W-G/Pro-W-G 169 (45.6) 254 (48.6) 1.30 (0.95–1.79) 46 (43.4) 0.92 (0.55–1.54) 1.22 (0.90–1.66)
Pro/Pro-WW-GG Pro-W-G/Pro-W-G 52 (14.0) 80 (15.3) 1.33 (0.85–2.07) 8 (7.6) 0.52 (0.21–1.26) 1.16 (0.76–1.79)
Arg/Pro-WM-GA Arg-W-G/Pro-M-A 8 (2.2) 19 (3.6)
1.61 (0.88–2.96)
6 (5.7)
2.14 (0.93–4.90) 1.72 (0.97–3.07)
Pro/Pro-WM-GA Pro-W-G/Pro-M-A 12 (3.2) 19 (3.6) 6 (5.7)
Pro/Pro-MM-AA Pro-M-A/Pro-M-A 2 (0.5) 1 (0.2) 0 (0.0)
Arg/Pro-WM-GG Arg-W-G/Pro-M-G 0 (0.0) 0 (0.0) 2 (1.9)
Arg/Pro-WW-GA Arg-W-G/Pro-W-A 0 (0.0) 1 (0.2) 0 (0.0)
Arg/Arg-WW-GA Arg-W-G/Arg-W-A 0 (0.0) 0 (0.0)
Total 371 523 106
1 (0.2)
aOther OSCC patients: including oropharynx and hypopharynx cancer patients.
bW: common allele (without replicative 16bp); M : rare allele (with replicative 16bp).
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contained two different mutations of the p53 gene and 15 samples
were not successfully sequenced. To reduce the complexity of
interpretation, cases with two mutations were excluded from
further analysis. Among the 101 mutations with an identified
sequence, 16 (15.8%) were deletions or insertions, 53 (52.5%) were
G:C to A:T transitions and 17 (16.8%) were G:C to T:A
transversions. The forms of mutation were not significantly
different between individuals with two Pro-W-G alleles and those
with either one or no Pro-W-G alleles (data not shown).
Tumour samples from 172 informative male oral cavity cancer
patients for p53 gene exon 4 were examined for LOH of the p53
gene. Of the 172 OSCCs, 72 (41.9%) showed LOH (Table 4). Among
the 72 OSCCs with LOH of the p53 gene, Pro allele loss was found
in 53 (73.6%) of the tumours. The frequency of LOH of p53 was not
associated with age, cigarette smoking, AQ chewing or alcohol
drinking. However, stage IV tumours had a slightly higher
frequency (33/66, 50.0%) of p53 LOH than stage I–III tumours
(39/106, 36.8%) (P¼0.09 by w
2). It is also interesting to note that
alcohol drinking would seem to increase the frequency of Arg allele
loss (OR¼10.56; 95% CI, 1.23–234.94) among cigarette smokers
and AQ chewers.
The status of p53 gene mutation was known for 94 tumour
samples from 172 informative male oral cavity cancer patients for
p53 gene exon 4. Of the 94 OSCCs, 67 (71.3%) showed alterations
(mutation, LOH or both) of p53 gene (Table 5). The frequency of
LOH of p53 was not different between 46 p53-mutated OSCCs and
48 p53-normal OSCCs (52.2 vs 43.8%, P¼0.41 by w
2). However,
LOH was more likely to appear at late than early tumour stage (14
events for stage IV vs seven events for stage I–III), while mutation
occurred at the early tumour stage (16 events for stage I–III vs six
events for stage IV). Therefore, stage IV tumours had a slightly
higher frequency (26/45, 57.8%) of p53 LOH than stage I–III
tumours (19/49, 38.8%) (P¼0.07 by w
2). Furthermore, a significant
cumulative effect of mutation of p53 and tumour stage on LOH of
p53 was observed (P¼0.03 by w
2 trend test). It is also interesting to
note that stage IV tumours had a slightly higher frequency (20/26,
76.9%) of Pro allele loss than stage I–III tumours (11/19, 57.9%)
(P¼0.17 by w
2) regardless of p53 mutation. The frequency of
p53 mutation was not different between 31 OSCCs having Pro
allele loss and 14 OSCCs with Arg allele loss (51.6 vs 57.1%,
P¼0.73 by w
2).
DISCUSSION
p53 has a critical role in cell-cycle control, apoptosis and DNA
repair (Vogelstein et al, 2000). Among the more than 10 DNA
sequence polymorphisms identified, the codon 72 polymorphism
(Arg/Pro) has been explored in depth for a potential association
Table 3 Association of p53 haplotypes and p53 gene mutations in oral cavity cancer
p53 haplotypes (exon
4–intron 3–intron 6)
Mutations detected/
tumours tested (%) OR (95% CI) OR (95% CI)
Adjusted OR
(95% CI)
a
Pro-W-G/Pro-W-G 25/66 (37.9) 1 1 1
Arg-W-G/Pro-W-G 57/105 (54.3) 2.95 (0.99–3.84)
1.99 (1.08–3.68)
1.98 (1.10–3.56)
Arg-W-G/Arg-W-G 29/54 (53.7) 1.90 (0.86–4.22)
Arg-W-G/Pro-M-A 6/11 (54.6)
2.32 (0.87–6.24)
Arg-W-G/Arg-W-A 1/1 (100.00)
Pro-W-G/Pro-M-A 9/16 (56.3)
Pro-M-A/Pro-M-A 1/1 (100.00)
aAdjusted for age, cigarette smoking, alcohol drinking, AQ chewing and XRCC1 399Gln polymorphism.
Table 4 Stratification analysis of the risk factors for oral cavity cancer and the frequency of LOH of the p53 gene
Cigarette smoking AQ chewing Alcohol drinking LOH/informative cases (%) Lost Pro allele/LOH cases (%) OR (95% CI)
+ + + 37/91 (40.7) 25/37 (67.6) 1
++   23/54 (42.6) 22/23 (95.7) 10.56 (1.23–234.94)
  + + 2/4 (50.00) 1/2 (50.0)
0.48 (0.10–2.17)
  +   0/4 (0.00)
+   + 5/8 (62.50) 2/5 (40.0)
+    4/7 (57.1) 2/4 (50.0)
   +
     1/4 (25.00) 1/1 (100.0)
Total 72/172 (41.9) 53/72 (73.6)
_
_ _
Table 5 Association of mutation of p53, tumour stage and the frequency of LOH of the p53 gene in oral cavity cancer
Mutation of p53 Tumour stage LOH/informative cases (%) OR (95% CI)* Lost Pro allele/LOH cases (%) OR (95% CI)
No I–III 7/21 (33.3) 1 4/7 (57.1) 1
Yes I–III 12/28 (42.9) 1.50 (0.40–5.75) 7/12 (58.3)
No IV 14/27 (51.0) 2.15 (0.57–8.35) 11/14 (78.6) 2.42 (0.56–10.77)
Yes IV 12/18 (66.7) 4.00 (0.88–19.32) 9/12 (75.0)
Total 45/94 (47.9) 31/45 (68.9)
*P¼0.03 by w
2 trend test.
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swith cancer. Although this polymorphism has been implied to be
associated with certain cancer types (Yu et al, 1999; Fan et al, 2000;
Shepherd et al, 2000), Sun et al (1999) reviewed 31 epidemiological
case–control studies and suggested that codon 72 allelism did not
have an impact on human cancer risk. The present study found
that there was no significant difference in the frequency of codon
72 genotype between patients and referent controls (P¼0.27).
Recently, five case–control studies have been conducted to
investigate an association between the p53 codon 72 polymorph-
ism and the risk of squamous cell carcinoma of the head and neck
(SCCHN), but none of them have found a positive association
(Hamel et al, 2000; McWilliams et al, 2000; Summersgill et al,
2000; Shen et al, 2002; Mitra et al, 2003). Taken together, these
results suggested that codon 72 allelism does not seem to have an
impact on human cancer risk, especially for SCCHN, although
Dumont et al (2003) had demonstrated that the Arg72 form of p53
was at least five times better at inducing apoptosis than the Pro72
variant.
The difference in overall haplotype frequency between patients
and referent controls was not significant in the present study
(P¼0.22). However, it is interesting to note that the rare
haplotypes (rare allele in introns 3 and 6) were slightly associated
with a risk of oral cancer (OR¼1.72; 95% CI, 0.97–3.07) (Table 2).
Recently, Gemignani et al (2004) have observed that a rare allele in
intron 3 was associated with an increased risk of colorectal cancer
and reduced basal levels of p53 mRNA in immortalised
lymphoblastoid cell lines. Taken together, these results could
support the speculation by Wu et al (2002) that introns 3 and 6
rare alleles might exert a functional effect, because as the copy
number of the rare allele in introns 3 and 6 is increased, the level of
the apoptotic index is decreased.
In Taiwan, most of male oral cavity cancer patients have a
history of both habitual cigarette smoking and AQ chewing. In the
present study, among 167 male OSCC patients informative for p53
gene exon 4, 141 (84.4%) have a history of both habitual cigarette
smoking and AQ chewing. Among these 141 OSCC patients, 91
(64.5%) patients also had a history of habitual alcohol drinking.
The frequency of LOH for p53 did not differ between patients with
and without alcohol drinking. However, interestingly, almost all of
the patients (95.5%, 21/22) without alcohol drinking had lost the
Pro allele, whereas only 68.4% (26/38) of the patients with alcohol
drinking had lost the Pro allele. In this study, we did not determine
which allele was mutated in the p53-mutated oral cavity cancer
patients with germline heterozygosity (Arg/Pro). Further studies to
determine the biological mechanism by which there is selection for
different codon 72 alleles by alcohol drinking are thus desirable.
In the present study, we found that OSCC patients with the
Arg72 allele had a significantly higher frequency of p53 mutation
than those with Pro/Pro genotype among patients with common
alleles of introns 3 and 6 (OR¼1.93; 95% CI, 1.03–3.63). In
addition, 73.6% (53/72) of those who showed LOH of the p53 gene
had lost the Pro allele. These results are consistent with those
reported by other authors for some tumour types, in which it has
been pointed out that LOH of p53 occurs more commonly for the
Pro allele and that there is a preferential mutation of the Arg72
allele (Brooks et al, 2000; Marin et al, 2000; Tada et al, 2001;
Furihata et al, 2002; Anzola et al, 2003). Based on the
reports assigning a higher apoptotic potential to the Arg allele
(Wu et al, 2002) and the current data, we could hypothesise that
the cells carrying an Arg allele require further p53 mutations to
increase their tumorigenic potential, while Pro/Pro cells could
undergo this procedure with fewer damage. Indeed, Marin et al
(2000) and Tada et al (2001) found that the p53 mutant acts as a
more potent inhibitor of p73 activity when p53 has Arg72 rather
than Pro72. Additional comprehensive studies using this series of
samples will be needed to elucidate the association between
polymorphisms within p53 and the mutant behaviour of p53 in
OSCCs associated with cigarette smoking, AQ chewing and alcohol
drinking.
The two-hit paradigm of tumour suppressor gene mutation has
held sway for many years. Recently, Venkatachalam et al (1998)
found that a high proportion of the tumours from the p53þ/ 
mice retained an intact, functional, wild-type allele. This result
indicates that mere reduction in p53 levels may be sufficient to
promote tumorigenesis. Although p53 mutation accompanied by
complete loss of the wild-type allele is the most frequent event
observed in many human cancers (Greenblatt et al, 1994), we
found no preference of mutation with LOH (n¼24), mutation
without LOH (n¼22) or LOH without mutation (n¼21) in 94
Taiwanese OSCCs with germline heterozygosity in codon 72 (Arg/
Pro). Furthermore, LOH was more likely to appear at late than
early tumour stage (14 for stage IV vs seven for stage I–III), while
mutation was occurred at the early tumour stage (16 for stage I–III
vs six for stage IV). These results support the hypothesis that
haploinsufficiency of p53 is in itself likely to contribute to tumour
progression and the mutant form of p53 has a dominant gain-of-
function activity or it may block the wild-type protein by acting as
a dominant negative (Santarosa and Ashworth, 2004).
In conclusion, we found that p53 codon 72 polymorphism may
not be a dominant factor for predisposition to OSCCs in Taiwan.
However, the present study revealed that (a) the Arg allele is
associated with p53 mutations, (b) the Pro allele is preferentially
lost in OSCCs associated with cigarette smoking and AQ chewing,
while the frequency of Arg allele loss is increased with alcohol
drinking, and (c) haploinsufficiency of p53 is in itself likely to
contribute to tumour progression in Taiwanese OSCCs.
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